"Our work to deliver a safe and effective vaccine has never been more urgent", Pfizer CEO Albert Bourla said in a statement. Pfizer said its shot being developed with BioNTech was 95% effective in a final analysis of clinical-trial data and it's applying to the U.S. FDA for emergency-use authorization.
"Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential", Pfizer CEO Albert Bourla said.
Pfizer and another U.S. company, Moderna, have broken all vaccine development speed records in their race for a cure over the last nine months.
The official added that the European Union will pay 10 euros a pop for 225 million doses of CureVac's vaccine candidate, down from 12 euros per shot price tag which the company initially suggested.
The European Medicines Agency is in daily contact with the U.S. Food and Drug Administration about the evaluation of the vaccines in order to "synchronize" assessment, said European Commission President Ursula von der Leyen. "Not only with Moderna-the government is also in communication with Pfizer, Serum Institute, Bharat Biotech and Zydus Cadila for their COVID-19 vaccine candidate in terms of safety, immunogenicity and efficacy", a senior government official said.
The news will add to the confidence that a vaccine can help end the pandemic.
The extraordinary results have sparked euphoria as the unprecedented compression of vaccine development timelines from years to months looks to be paying off. USA regulators hope to have 20 million vaccine doses each from Moderna and Pfizer available for distribution in late December.